Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10726411 | 0.83 | METAP2 (0.40) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL27787791 | 0.81 | METAP2 (0.44) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL434033 | 0.81 | METAP2 (0.44) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL277595 | 0.75 | METAP2 (0.47) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL28139921 | 0.74 | METAP2 (0.41) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL28184057 | 0.74 | — | — | |
| SCHEMBL2011131 | 0.71 | METAP2 (0.47) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL3801779 | 0.71 | METAP2 (0.47) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL375955 | 0.71 | SMN1; SMN2 (0.52) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL5632 | 0.71 | NUDT1 (0.50) | METAP2METAP1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110177791-A | Amino-triazolopyridine compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2019-08-27 | — | — | CN | claimed |
| CN-109641904-A | The sulphur imido acyl group purine ketone compound that 7- for treating and preventing virus infection replaces | 豪夫迈·罗氏有限公司 | 2019-04-16 | — | — | CN | claimed |
| CN-109608462-A | A kind of 7- alkyl -9- alcoxyl/mercaptopurine -8- ketone compounds and its synthetic method and the application in drug | 华南理工大学 | 2019-04-12 | — | — | CN | claimed |
| CN-108473495-A | Purinones as ubiquitin-specific protease 1 inhibitors | 福马治疗有限公司 | 2018-08-31 | — | — | CN | claimed |
| CN-107580596-A | For treating and preventing the new sulphur imido acyl group purinone compound and derivative of virus infection | 豪夫迈·罗氏有限公司 | 2018-01-12 | — | — | CN | claimed |
| CN-107108628-A | Adenine derivatives useful for the treatment of allergic diseases or other inflammatory conditions | 葛兰素史密丝克莱恩生物有限公司 | 2017-08-29 | — | — | CN | claimed |
| CN-104395313-B | Azabicyclo replacing and application thereof | 拜耳知识产权有限责任公司 | 2017-03-08 | — | — | CN | claimed |
| CN-110312720-A | The inhibitor of bruton's tyrosine kinase | 吉利德科学公司 | 2019-10-08 | — | — | CN | disclosed |
| CN-110177791-A | Amino-triazolopyridine compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2019-08-27 | — | — | CN | disclosed |
| CN-109996544-A | Treatment of cancer combination | 加利福尼亚大学董事会 | 2019-07-09 | — | — | CN | disclosed |
| CN-109890417-A | The treatment of cancer and/or prophylactic compositions | 东丽株式会社 | 2019-06-14 | — | — | CN | disclosed |
| CN-109715214-A | Combination therapy of a TLR7 agonist and an HBV capsid assembly inhibitor | 豪夫迈·罗氏有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-109641904-A | The sulphur imido acyl group purine ketone compound that 7- for treating and preventing virus infection replaces | 豪夫迈·罗氏有限公司 | 2019-04-16 | — | — | CN | disclosed |
| EP-2133343-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| EP-2003135-A9 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-2003135-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1732929-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | Nissan Chemical Industries, Ltd. (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090357-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | CYP2C19, CYP2C9, CYP1A2 | METAP2 3343/4885METAP1 3083/4885NPY5R 2133/4885 |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | METAP2 4372/4885METAP1 4525/4885NPY5R 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.